Posted on 02/08/2010 in Pharmacy Supplier News Teva has hailed its performance in the second quarter of 2010 after experiencing a record-breaking performance in terms of sales and growth.
The generic medicines manufacturer saw its net sales for the quarter increase to $3.8 billion (2.4 billion pounds), representing an organic growth of 12 per cent year-on-year.
All of the company's business units posted improved figures during the three-month period, while its successful multiple sclerosis (MS) treatment Copaxone saw sales increase by 13 per cent, retaining its position as the world's leading MS drug.
In addition, the firm has also been able to secure financing for the planned acquisition of ratiopharm, a move which will further strengthen Teva's generics offering.
Shlomo Yanai, Teva's president and chief executive officer, said: "This was truly a superb quarter in which Teva achieved record-breaking results, including outstanding organic growth."
Last week, Teva announced that it will be moving to extend support of the UK pharmacy sector by offering bursaries to underprivileged students for the third consecutive year. Other news stories from 02/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
